Renal Cell Carcinoma

Pembrolizumab and lenvatinib show promising survival rates and durable responses in advanced non-clear cell renal cell carcinoma, transforming treatment standards.

During a live event, Nataliya Mar, MD, discussed a non–clear cell renal cell carcinoma trial of cabozantinib/nivolumab and how it compares to other combinations.

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

Explore the evolving treatment strategies for metastatic clear cell renal cell carcinoma, highlighting innovative combination therapies and their efficacy.

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.

Bradley A. McGregor, MD, discusses the advancements in treating metastatic renal cell carcinoma.

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies.

Explore the complexities of non-clear cell renal cell carcinoma, its treatment challenges, and promising immunotherapy advancements for better patient outcomes.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.

David A. Braun, MD, PhD, reveals how integrating tumor and circulating biomarkers enhances treatment response predictions in advanced renal cell carcinoma.